The US government’s plan to allow Medicare and Medicaid to cover Eli Lilly’s weight loss drugs

The US government’s plan to allow Medicare and Medicaid to cover Eli Lilly’s weight loss drugs starting in 2026 and 2027. This move includes Eli Lilly’s Mounjaro and Zepbound, starting in April 2026 for Medicaid and January 2027 for Medicare.

This news has led to a rise in Eli Lilly’s stock, indicating positive investor sentiment.

Also, Eli Lilly and Company inaugurated a new technology and innovation site in Hyderabad, which would serve as a strategic hub for advanced digital and technology capabilities.